SELLAS Life Sciences Group Inc buy Heureka
Start price
27.02.20
/
50%
€2.39
Target price
09.03.20
€3.00
Performance (%)
-23.10%
End price
09.03.20
€1.84
Summary
This prediction ended on 09.03.20 with a price of €1.84. The prediction for SELLAS Life Sciences Group Inc disappointed with a performance of -23.10%. Heureka has 50% into this predictionSELLAS Life Sciences is a clinical-stage biopharmaceutical company focused on the development of novel cancer immunotherapies for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, is a cancer immunotherapy being developed for the treatment of acute myeloid leukemia (AML) and ovarian cancer. SELLAS Life Sciences is listed on the NASDAQ stock exchange under the symbol RXII.
Performance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| SELLAS Life Sciences Group Inc | 7.327% | 7.327% | -27.151% | -85.469% |
| iShares Core DAX® | -0.612% | 0.567% | 12.585% | 14.838% |
| iShares Nasdaq 100 | -3.018% | -3.205% | 26.208% | 38.328% |
| iShares Nikkei 225® | -2.647% | 0.330% | 9.482% | 5.652% |
| iShares S&P 500 | -1.932% | -1.126% | 23.191% | 38.791% |